The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL)

Autor:	Barbara Eichhorst, Michael Gregor, Christian H. Geisler, Arnon P. Kater, Patrick Thornton, Niemann Carsten, Marinus H. J. van Oers, Tamar Tadmor, Eric Eldering, Matthias Ritgen, Stephan Stilgenbauer, Karl Anton Kreuzer, Michael Hallek, Kirsten Fischer, Jasmin Bahlo, Von Tresckow Julia, Moritz Fürstenau, Anna-Maria Fink
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology Cancer Research medicine.medical_specialty Standard of care business.industry Chronic lymphocytic leukemia Tp53 mutation medicine.disease First line treatment 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Chemoimmunotherapy 030220 oncology & carcinogenesis Internal medicine medicine business
Zdroj:	Journal of Clinical Oncology. 36:TPS7582-TPS7582
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.tps7582
Popis:	TPS7582Background: Chemoimmunotherapy (CIT) is still standard of care in first line treatment of fit CLL patients (pts) without del(17p) or TP53 mutation. However, CIT is often associated with side...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::87cf2da9a296e481d203bd3695999740 https://doi.org/10.1200/jco.2018.36.15_suppl.tps7582 Zobrazit plný text záznamu